Scott G. Ginn - 14 Aug 2025 Form 4 Insider Report for AMEDISYS INC (AMED)

Reporting relationship: EVP, CFO & COO
Issuer ticker: AMED
Reported as of: 14 Aug 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 14 Aug 2025, 16:02:22 UTC
Prior SEC filing: 03 Jul 2025
Next SEC filing: 23 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ Jennifer Guckert Griffin, pursuant to a power of attorney

Key filing fact

Scott G. Ginn filed Form 4 for AMEDISYS INC (AMED) on 14 Aug 2025.

Key facts

This page summarizes Scott G. Ginn's Form 4 filing for AMEDISYS INC (AMED).
13 reported transactions and 8 derivative rows are listed below.
Accepted by SEC: 14 Aug 2025, 16:02.

Change

Previous filing in this sequence was filed on 03 Jul 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001543701 Primary reporting owner

Ginn Scott G

Relationship: EVP, CFO & COO
Address: 3854 AMERICAN WAY, SUITE A, BATON ROUGE
Signature: /s/ Jennifer Guckert Griffin, pursuant to a power of attorney
Signature date: 14 Aug 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AMED transaction

Common Stock

Disposed to Issuer

Transaction value
Shares: -31,211
Change %: -34%
Price
Shares after: 60,518
Date: 14 Aug 2025
Ownership: Direct
Footnotes: F1

AMED transaction

Common Stock

Disposed to Issuer

Transaction value
Shares: -60,518
Change %: -100%
Price
Shares after: 0
Date: 14 Aug 2025
Ownership: Direct
Footnotes: F2

AMED transaction

Common Stock

Options Exercise

Transaction value: $0
Shares: +10,399
Change %
Price: $0.000000
Shares after: 10,399
Date: 14 Aug 2025
Ownership: Direct
Footnotes: F3, F4

AMED transaction

Common Stock

Disposed to Issuer

Transaction value
Shares: -10,399
Change %: -100%
Price
Shares after: 0
Date: 14 Aug 2025
Ownership: Direct
Footnotes: F3, F4

AMED transaction

Common Stock

Disposed to Issuer

Transaction value
Shares: -2,714
Change %: -100%
Price
Shares after: 0
Date: 14 Aug 2025
Ownership: Through 401(k) Plan
Footnotes: F5

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AMED transaction Derivative

Restricted Stock Unit (Performance-Based Vesting)

Options Exercise

Transaction value
Shares: -10,399
Change %: -100%
Price
Shares after: 0
Date: 14 Aug 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 10,399
Exercise price
Footnotes: F3, F4

AMED transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -424
Change %: -100%
Price
Shares after: 0
Date: 14 Aug 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 424
Exercise price: $58.69
Footnotes: F6, F7

AMED transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -6,995
Change %: -100%
Price
Shares after: 0
Date: 14 Aug 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 6,995
Exercise price: $49.25
Footnotes: F6, F7

AMED transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -4,294
Change %: -100%
Price
Shares after: 0
Date: 14 Aug 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 4,294
Exercise price: $127.11
Footnotes: F6, F7

AMED transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -2,997
Change %: -100%
Price
Shares after: 0
Date: 14 Aug 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 2,997
Exercise price: $198.81
Footnotes: F6, F7

AMED transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -3,200
Change %: -100%
Price
Shares after: 0
Date: 14 Aug 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 3,200
Exercise price: $295.20
Footnotes: F6, F7

AMED transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -6,119
Change %: -100%
Price
Shares after: 0
Date: 14 Aug 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 6,119
Exercise price: $143.25
Footnotes: F7, F8

AMED transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -8,627
Change %: -100%
Price
Shares after: 0
Date: 14 Aug 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 8,627
Exercise price: $91.77
Footnotes: F7, F9

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Scott G. Ginn is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 9 footnotes

Footnote F1

On August 14, 2025, UnitedHealth Group Incorporated ("UnitedHealth Group") acquired Amedisys, Inc. (the "Issuer") pursuant to that certain Agreement and Plan of Merger dated as of June 26, 2023 (as modified by the waiver, dated December 26, 2024, the "Merger Agreement") by and among the Issuer, UnitedHealth Group and Aurora Holdings Merger Sub Inc., a wholly owned subsidiary of UnitedHealth Group ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly owned subsidiary of UnitedHealth Group. At the effective time of the Merger (the "Effective Time"), each issued and outstanding share of common stock, par value $0.001 per share, of the Issuer (the "Common Stock") (other than certain excluded shares) automatically converted into the right to receive $101 per share in cash (the "Per Share Merger Consideration"), without interest and less any applicable withholding tax.

Footnote F2

Pursuant to the Merger Agreement, outstanding restricted stock units ("RSUs") of the Issuer were automatically converted into UnitedHealth Group RSUs, calculated by multiplying the number of Issuer RSUs by the quotient obtained by dividing the Per Share Merger Consideration by the volume-weighted average of the closing sale price per share of UnitedHealth Group common stock on each of the five full consecutive trading days ending on and including the third business day prior to the Merger closing date (the "Equity Award Exchange Ratio"), which continue to be subject to the same terms and conditions (including vesting and settlement terms) as were applicable to the Issuer RSUs.

Footnote F3

The performance-based restricted stock units ("PSUs") were scheduled to cliff vest following a three-year performance period ending December 31, 2025 based on the Company's achievement of Adjusted EBITDA for 2023, as modified by the Company's three-year total shareholder return percentile rank compared to a pre-established comparator group (the "TSR Modifier"). On February 20, 2024, the Compensation Committee of the Issuer's Board of Directors certified achievement of 2023 Adjusted EBITDA performance at 127.23%, thereby resulting in the Reporting Person earning 10,399 PSUs. The amount reported represents 127.23% of the target number of PSUs originally awarded and assumes performance at target (100%) for the TSR Modifier pursuant to the terms of the Merger Agreement.

Footnote F4

Pursuant to the Merger Agreement, PSUs of the Issuer were automatically converted into time-based vesting UnitedHealth Group RSUs, with the number of shares of UnitedHealth Group common stock subject to the UnitedHealth Group RSUs equal to (i) the number of shares of Common Stock underlying the Issuer PSUs based on the amount actually earned for the 2023 Adjusted EBITDA performance measure and assuming target performance (100%) for the TSR Modifier, multiplied by (ii) the Equity Award Exchange Ratio. Except as described herein, the UnitedHealth Group RSUs will continue to be subject to the same terms and conditions as were applicable to the Issuer PSUs, and will vest on December 31, 2025.

Footnote F5

As of the Effective Time, each of the shares of the Issuer's Common Stock that the Reporting Person previously reported as beneficially owned under the Issuer's 401(k) plan was converted into the right to receive the Per Share Merger Consideration.

Footnote F6

These options are fully vested.

Footnote F7

In connection with the Merger, stock option awards of the Issuer were automatically converted into an option to purchase a number of shares of common stock of UnitedHealth Group equal to the product of (i) the number of shares of Common Stock subject to the Issuer stock option multiplied by (ii) Equity Award Exchange Ratio, at an exercise price per share equal to (i) the exercise price of the Issuer stock option divided by (ii) the Equity Award Exchange Ratio. Except as described herein, the UnitedHealth Group options will continue to be subject to the same terms and conditions as were applicable to the existing Issuer stock option.

Footnote F8

4,589 of the options are fully vested; 1,530 of the options vest on February 20, 2026.

Footnote F9

5,751 of the options are fully vested; 2,876 of the options vest on February 20, 2026.